BENGALURU/HYDERABAD (Reuters) – India’s Sun Pharmaceutical Industries reported third-quarter profit above estimates on Wednesday, driven by strong sales in key markets such as the United States.
The company reported a consolidated profit after tax of 25.24 billion rupees ($304 million) for the quarter ended Dec. 31, beating analysts’ estimate of 24.17 billion rupees as per LSEG data.
($1 = 83.0000 Indian rupees)
(This story has been corrected to say company reported consolidated profit after tax of 25.24 billion rupees, not 24.24 billion rupees, in paragraph 2)
(Reporting by Kashish Tandon in Bengaluru and Rishika Sadam in Hyderabad; Editing by Mrigank Dhaniwala and Varun H K)
Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content.